Global Antivenom Drugs Market Growth 2022-2028
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Antivenom Drugs Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Antivenom Drugs by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Antivenom Drugs by Country/Region, 2017, 2022 & 2028
- 2.2 Antivenom Drugs Segment by Type
- 2.2.1 Antineurotoxin
- 2.2.2 Anticirculatory Toxin
- 2.2.3 Antimixing Toxin
- 2.3 Antivenom Drugs Sales by Type
- 2.3.1 Global Antivenom Drugs Sales Market Share by Type (2017-2022)
- 2.3.2 Global Antivenom Drugs Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Antivenom Drugs Sale Price by Type (2017-2022)
- 2.4 Antivenom Drugs Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinical Laboratory
- 2.4.3 Field Rescue Station
- 2.4.4 Other
- 2.5 Antivenom Drugs Sales by Application
- 2.5.1 Global Antivenom Drugs Sale Market Share by Application (2017-2022)
- 2.5.2 Global Antivenom Drugs Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Antivenom Drugs Sale Price by Application (2017-2022)
3 Global Antivenom Drugs by Company
- 3.1 Global Antivenom Drugs Breakdown Data by Company
- 3.1.1 Global Antivenom Drugs Annual Sales by Company (2020-2022)
- 3.1.2 Global Antivenom Drugs Sales Market Share by Company (2020-2022)
- 3.2 Global Antivenom Drugs Annual Revenue by Company (2020-2022)
- 3.2.1 Global Antivenom Drugs Revenue by Company (2020-2022)
- 3.2.2 Global Antivenom Drugs Revenue Market Share by Company (2020-2022)
- 3.3 Global Antivenom Drugs Sale Price by Company
- 3.4 Key Manufacturers Antivenom Drugs Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Antivenom Drugs Product Location Distribution
- 3.4.2 Players Antivenom Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Antivenom Drugs by Geographic Region
- 4.1 World Historic Antivenom Drugs Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Antivenom Drugs Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Antivenom Drugs Annual Revenue by Geographic Region
- 4.2 World Historic Antivenom Drugs Market Size by Country/Region (2017-2022)
- 4.2.1 Global Antivenom Drugs Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Antivenom Drugs Annual Revenue by Country/Region
- 4.3 Americas Antivenom Drugs Sales Growth
- 4.4 APAC Antivenom Drugs Sales Growth
- 4.5 Europe Antivenom Drugs Sales Growth
- 4.6 Middle East & Africa Antivenom Drugs Sales Growth
5 Americas
- 5.1 Americas Antivenom Drugs Sales by Country
- 5.1.1 Americas Antivenom Drugs Sales by Country (2017-2022)
- 5.1.2 Americas Antivenom Drugs Revenue by Country (2017-2022)
- 5.2 Americas Antivenom Drugs Sales by Type
- 5.3 Americas Antivenom Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Antivenom Drugs Sales by Region
- 6.1.1 APAC Antivenom Drugs Sales by Region (2017-2022)
- 6.1.2 APAC Antivenom Drugs Revenue by Region (2017-2022)
- 6.2 APAC Antivenom Drugs Sales by Type
- 6.3 APAC Antivenom Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Antivenom Drugs by Country
- 7.1.1 Europe Antivenom Drugs Sales by Country (2017-2022)
- 7.1.2 Europe Antivenom Drugs Revenue by Country (2017-2022)
- 7.2 Europe Antivenom Drugs Sales by Type
- 7.3 Europe Antivenom Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Antivenom Drugs by Country
- 8.1.1 Middle East & Africa Antivenom Drugs Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Antivenom Drugs Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Antivenom Drugs Sales by Type
- 8.3 Middle East & Africa Antivenom Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Antivenom Drugs
- 10.3 Manufacturing Process Analysis of Antivenom Drugs
- 10.4 Industry Chain Structure of Antivenom Drugs
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Antivenom Drugs Distributors
- 11.3 Antivenom Drugs Customer
12 World Forecast Review for Antivenom Drugs by Geographic Region
- 12.1 Global Antivenom Drugs Market Size Forecast by Region
- 12.1.1 Global Antivenom Drugs Forecast by Region (2023-2028)
- 12.1.2 Global Antivenom Drugs Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Antivenom Drugs Forecast by Type
- 12.7 Global Antivenom Drugs Forecast by Application
13 Key Players Analysis
- 13.1 Bioclone Institute
- 13.1.1 Bioclone Institute Company Information
- 13.1.2 Bioclone Institute Antivenom Drugs Product Offered
- 13.1.3 Bioclone Institute Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Bioclone Institute Main Business Overview
- 13.1.5 Bioclone Institute Latest Developments
- 13.2 Pfizer Inc
- 13.2.1 Pfizer Inc Company Information
- 13.2.2 Pfizer Inc Antivenom Drugs Product Offered
- 13.2.3 Pfizer Inc Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Pfizer Inc Main Business Overview
- 13.2.5 Pfizer Inc Latest Developments
- 13.3 F. Hoffmann-La Roche Ltd
- 13.3.1 F. Hoffmann-La Roche Ltd Company Information
- 13.3.2 F. Hoffmann-La Roche Ltd Antivenom Drugs Product Offered
- 13.3.3 F. Hoffmann-La Roche Ltd Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 F. Hoffmann-La Roche Ltd Main Business Overview
- 13.3.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.4 Merck KGaA
- 13.4.1 Merck KGaA Company Information
- 13.4.2 Merck KGaA Antivenom Drugs Product Offered
- 13.4.3 Merck KGaA Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Merck KGaA Main Business Overview
- 13.4.5 Merck KGaA Latest Developments
- 13.5 Rare Disease Therapeutics, Inc
- 13.5.1 Rare Disease Therapeutics, Inc Company Information
- 13.5.2 Rare Disease Therapeutics, Inc Antivenom Drugs Product Offered
- 13.5.3 Rare Disease Therapeutics, Inc Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Rare Disease Therapeutics, Inc Main Business Overview
- 13.5.5 Rare Disease Therapeutics, Inc Latest Developments
- 13.6 VINS Bioproducts Ltd
- 13.6.1 VINS Bioproducts Ltd Company Information
- 13.6.2 VINS Bioproducts Ltd Antivenom Drugs Product Offered
- 13.6.3 VINS Bioproducts Ltd Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.6.4 VINS Bioproducts Ltd Main Business Overview
- 13.6.5 VINS Bioproducts Ltd Latest Developments
- 13.7 BTG International Inc
- 13.7.1 BTG International Inc Company Information
- 13.7.2 BTG International Inc Antivenom Drugs Product Offered
- 13.7.3 BTG International Inc Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.7.4 BTG International Inc Main Business Overview
- 13.7.5 BTG International Inc Latest Developments
- 13.8 Incepta Pharma
- 13.8.1 Incepta Pharma Company Information
- 13.8.2 Incepta Pharma Antivenom Drugs Product Offered
- 13.8.3 Incepta Pharma Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 Incepta Pharma Main Business Overview
- 13.8.5 Incepta Pharma Latest Developments
- 13.9 Bharat Serums and Vaccines Limited
- 13.9.1 Bharat Serums and Vaccines Limited Company Information
- 13.9.2 Bharat Serums and Vaccines Limited Antivenom Drugs Product Offered
- 13.9.3 Bharat Serums and Vaccines Limited Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 Bharat Serums and Vaccines Limited Main Business Overview
- 13.9.5 Bharat Serums and Vaccines Limited Latest Developments
- 13.10 Hamilton Company
- 13.10.1 Hamilton Company Company Information
- 13.10.2 Hamilton Company Antivenom Drugs Product Offered
- 13.10.3 Hamilton Company Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.10.4 Hamilton Company Main Business Overview
- 13.10.5 Hamilton Company Latest Developments
- 13.11 B. Braun SE
- 13.11.1 B. Braun SE Company Information
- 13.11.2 B. Braun SE Antivenom Drugs Product Offered
- 13.11.3 B. Braun SE Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.11.4 B. Braun SE Main Business Overview
- 13.11.5 B. Braun SE Latest Developments
- 13.12 Cardinal Health
- 13.12.1 Cardinal Health Company Information
- 13.12.2 Cardinal Health Antivenom Drugs Product Offered
- 13.12.3 Cardinal Health Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.12.4 Cardinal Health Main Business Overview
- 13.12.5 Cardinal Health Latest Developments
- 13.13 BD
- 13.13.1 BD Company Information
- 13.13.2 BD Antivenom Drugs Product Offered
- 13.13.3 BD Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.13.4 BD Main Business Overview
- 13.13.5 BD Latest Developments
- 13.14 Boston Scientific Corporation
- 13.14.1 Boston Scientific Corporation Company Information
- 13.14.2 Boston Scientific Corporation Antivenom Drugs Product Offered
- 13.14.3 Boston Scientific Corporation Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.14.4 Boston Scientific Corporation Main Business Overview
- 13.14.5 Boston Scientific Corporation Latest Developments
- 13.15 Alomone Labs
- 13.15.1 Alomone Labs Company Information
- 13.15.2 Alomone Labs Antivenom Drugs Product Offered
- 13.15.3 Alomone Labs Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.15.4 Alomone Labs Main Business Overview
- 13.15.5 Alomone Labs Latest Developments
- 13.16 Wyeth, LLC
- 13.16.1 Wyeth, LLC Company Information
- 13.16.2 Wyeth, LLC Antivenom Drugs Product Offered
- 13.16.3 Wyeth, LLC Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.16.4 Wyeth, LLC Main Business Overview
- 13.16.5 Wyeth, LLC Latest Developments
- 13.17 Serum Biotech
- 13.17.1 Serum Biotech Company Information
- 13.17.2 Serum Biotech Antivenom Drugs Product Offered
- 13.17.3 Serum Biotech Antivenom Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.17.4 Serum Biotech Main Business Overview
- 13.17.5 Serum Biotech Latest Developments
14 Research Findings and Conclusion
Antivenom drugs are used to treat venomous bites and stings, usually preferable in high-toxicity cases. Antivenin, venom antiserum, and antivenom immunoglobulin are the different other names of antivenom drugs. These medications can potentially reverse the effects of snake bites, and generally, an adequate therapeutic dose is injected. Additionally, these medications also help in kidney dialysis, artificial respiration, prosthesis as well as rehabilitation services.
The global market for Antivenom Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Antivenom Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Antivenom Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Antivenom Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Antivenom Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Antivenom Drugs players cover Bioclone Institute, Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck KGaA and Rare Disease Therapeutics, Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Antivenom Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Antivenom Drugs market, with both quantitative and qualitative data, to help readers understand how the Antivenom Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Antivenom Drugs market and forecasts the market size by Type (Antineurotoxin, Anticirculatory Toxin and Antimixing Toxin), by Application (Hospital, Clinical Laboratory, Field Rescue Station and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Antineurotoxin
Anticirculatory Toxin
Antimixing Toxin
Segmentation by application
Hospital
Clinical Laboratory
Field Rescue Station
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Bioclone Institute
Pfizer Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Rare Disease Therapeutics, Inc
VINS Bioproducts Ltd
BTG International Inc
Incepta Pharma
Bharat Serums and Vaccines Limited
Hamilton Company
B. Braun SE
Cardinal Health
BD
Boston Scientific Corporation
Alomone Labs
Wyeth, LLC
Serum Biotech
Chapter Introduction
Chapter 1: Scope of Antivenom Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global Antivenom Drugs market size (sales and revenue) and CAGR, Antivenom Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Antivenom Drugs sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Antivenom Drugs sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Antivenom Drugs market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Bioclone Institute, Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck KGaA, Rare Disease Therapeutics, Inc, VINS Bioproducts Ltd, BTG International Inc, Incepta Pharma and Bharat Serums and Vaccines Limited, etc.
Chapter 14: Research Findings and Conclusion